Bladder Cancer - Results from #400

Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review. July 15, 2024

Clinical, Pathological Characteristics and Progression of Urothelial Bladder Cancer in Young Adult Patients. Our Experience and Literature Review. July 12, 2024

Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. July 12, 2024

Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France. July 11, 2024

Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. July 11, 2024

Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience and follow-up proposal. July 11, 2024

DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group. July 11, 2024

Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma with Prognostic Implications. July 10, 2024

Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study. July 10, 2024

A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma. July 10, 2024

Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates. July 9, 2024

A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. July 9, 2024

Efficacy of FGFR Inhibitor Derazantinib in Metastatic Urothelial Carcinoma - Expert Commentary July 8, 2024

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations July 8, 2024

Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion. July 8, 2024

Contemporary survival in metastatic bladder cancer patients: A population-based study. July 8, 2024

Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding. July 8, 2024

Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. July 5, 2024

N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review. July 5, 2024

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. July 4, 2024

Page 21 of 525